Skip to main content

Table 1 Characteristics of patients in the efficacy analysis group

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Characteristics of Patients

n (%) or mean ± SD

Number

3316

Entry category

 

   Type 1 diabetes, n/%

40 (1.2%)

   Type 2 diabetes, n/%

3235 (97.6%)

   Diabetes (diagnosis unknown), n/%

37 (1.1%)

   FBG ≥ 6.1 [mmol/l], n/%

4 (0.1%)

Outpatients, n/%

3212 (96.9%)

Men, n/%

2074 (62.5%)

Age, mean/SD

61.0 ± 12.0

≥65 yeas, n/%

1400 (42.2%)

BMI (kg/m2), mean/SD

25.7 ± 3.7

Smoking, n/%

825 (24.9%)

Alcohol consumption, n/%

1129 (34.0%)

Complication, n/%

2397 (72.3%)

   Hepatic disease, n/%

339 (10.2%)

   Kidney disease, n/%

51 (1.5%)

   Hypertension, n/%

1614 (48.7%)

Heart disease, n/%

325 (9.8%)

Duration of hyperlipidemia (years), mean/SD

4.7 ± 4.3

Duration of diabetes (years), mean/SD

6.6 ± 5.9

Previous treatment of hyperlipidemia, n/%

602 (18.2%)

Previous treatment of diabetes, n/%

1977 (59.6%)

Total cholesterol (mmol/l), mean/SD

5.76 ± 1.03

LDL cholesterol (mmol/l), mean/SD

3.19 ± 0.95

HDL cholesterol (mmol/l), mean/SD

1.18 ± 0.33

TG (mmol/l), mean/SD

3.72 ± 2.45

HbA1c (%), mean/SD

7.69 ± 1.52

FBG (mmol/l), mean/SD

9.01 ± 3.49

  1. aStandard Deviation